Siemens (ETR:SIEGn) exceeded expectations in its fiscal second quarter, reporting a 29% jump in industrial profit to 3.24 ...

A study reports that people living in lower income neighborhoods were at a higher risk for hidradenitis suppurativa.

The latest quarterly results from a couple of major technology companies have soothed concerns about AI demand that prevailed ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) of 2025 from $18.8bn in Q4 2024 to $37.7bn ... GSK’s $1.15bn buy of IDRx, ...

This includes a near doubling of quarterly revenue to $10.2 million in Q4 2024, an increase of $4.8 million from Q4 2023, primarily due to the increase in production at Plomosas as well as a 24% ...

Revenue: $3.4 million in Q4 2024, down from $7.1 million in Q3 2024. Full Year Revenue: $27.7 million, up slightly from $27.5 million in 2023. Net Loss: $20.5 million for 2024, equating to $8.35 per ...

Adjusted EBITDA of $4.5 million for Q4, and $24.4 million for the full year excluding project sales proceeds from sale of Monte Do Carmo Received $34 million in Asset sale and Option payment ...